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Preoperative chemotherapy is a promising strategy in patients with early-stage resectable non-small-cell lung cancer (NSCLC);
optimal chemotherapy remains unclear. Clinical (c-) stage IB/II NSCLC patients were randomised to receive either two cycles of
docetaxel (D)–cisplatin (P) combination chemotherapy (D 60mgm
 2 and P 80mgm
 2 on day 1) every 3–4 weeks or three cycles
of D monotherapy (70mgm
 2) every 3weeks. Thoracotomy was performed 4–5 weeks (DP) or 3–4 weeks (D) after
chemotherapy. The primary end point was 1-year disease-free survival (DFS). From October 2002 to November 2003, 80 patients
were randomised. Chemotherapy toxicities were mainly haematologic and well tolerated. There were two early postoperative
deaths with DP (one intraoperative bleeding and one empyema). Pathologic complete response was observed in two DP patients.
Docetaxel–cisplatin was superior to D in terms of response rate (45 vs 15%) and complete resection rate (95 vs 87%). Both DFS and
overall survival were better in DP. Disease-free survival at 1, 2 and 4 years were 78, 65 and 57% with DP, and were 62, 44 and 36%
with D, respectively. Preoperative DP was associated with encouraging resection rate and DFS data, and phase III trials for c-stage IB/II
NSCLC are warranted.
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Surgery is the standard of care for clinical (c-) stage IB/II
non-small-cell lung cancer (NSCLC), but the treatment outcome
remains poor, with 5-year survival rates of 50% or less (Mountain,
1997; Goya et al, 2005). The majority of post-surgical relapse
occurs as distant metastases (Pisters and Le Chevalier, 2005);
therefore, effective systemic therapy is necessary. Recently,
a series of postoperative adjuvant chemotherapy trials reported
modest but significant improvement in survival, mainly in
patients with pathological stage II or IIIA NSCLC (Arriagada
et al, 2004; Scagliotti, 2005; Winton et al, 2005; Douillard et al,
2006). Compliance to the chemotherapy remains a problem
(Arriagada et al, 2004; Scagliotti, 2005; Winton et al, 2005;
Douillard et al, 2006).
On the other hand, previous small phase III trials had reported
that preoperative chemotherapy was better than surgery alone
in stage III NSCLC (Rosell et al, 1994; Roth et al, 1994). Recent
trials of preoperative platinum-based chemotherapy have reported
promising results in c-stage IB/II NSCLC (Pisters et al, 2000;
Depierre et al, 2002; Rosell et al, 2002). One advantage of the
preoperative chemotherapy is better tolerability and compliance.
No data are available, however, as to the optimal preoperative
therapy strategy for early-stage NSCLC. Although platinum-based
‘standard’ combination chemotherapy regimens have widely been
used and reported to be generally safe, results of randomised trials
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sreported nonsignificant but modest excess of post-surgical
morbidity and mortality (Depierre et al, 2002; Pisters et al,
2007). Monotherapy with an active agent is associated with lower
response rate, but less toxicity (Delbaldo et al, 2004); it might well
be favourable for preoperative therapy in early stage, when surgery
must not be compromised by adjuvant therapy.
Docetaxel (D) is a semisynthetic taxoid derived from the
European yew Taxus baccata. It is active against NSCLC either
in monotherapy (D)(Fossella et al, 1994; Francis et al, 1994;
Kunitoh et al, 1996) or in combination with cisplatin (DP)
(Zalcberg et al, 1998; Fossella et al, 2003). In advanced NSCLC, DP
was reported to be better than P–vinca combination (Fossella et al,
2003; Kubota et al, 2004), one of the ‘standard’ adjuvant therapies.
The DP combination was also reported to be active and promising
as preoperative chemotherapy in c-stage III NSCLC (Betticher
et al, 2006).
Docetaxel monotherapy, on the other hand, was reported to be
not inferior to DP, with better tolerability in advanced NSCLC
(Georgoulias et al, 2004). For stage III NSCLC, Mattson et al (2003)
reported the results of D as preoperative chemotherapy; it was
active, and did not compromise surgery.
On the basis of this rationale, we undertook a randomised phase
II trial of DP vs D in resectable, c-stage IB/II NSCLC. The
objectives of the study were to evaluate the safety and efficacy of
the preoperative chemotherapy and to select promising one for
future phase III trials. The primary end point was the disease-free
survival (DFS) rate at 1 year.
PATIENTS AND METHODS
Patient eligibility criteria
Patients with untreated, histologically or cytologically documented
NSCLC with clinical stage IB (c-T2N0M0), IIA (c-T1N1M0) or IIB
(c-T2N1M0 or T3N0M0) were eligible for study entry. Each patient
was required to meet the following criteria: 20–74 years of age,
Eastern Cooperative Oncology Group (ECOG) performance status
(PS) of 0 or 1; measurable disease; and adequate organ function
(leukocyte count X4000/ml and p12000/ml, neutrophil count
X2000/ml, platelet count X10
5/ml, haemoglobin X10.0gdl
 1,
serum creatinine pthe upper limit of the institutional normal
range (ULN), creatinine clearance calculated by the Cockcroft–
Gault formula X60mlmin
 1, serum bilirubin pULN, serum ALT
and AST p2 ULN and PaO2 X70mmHg). Women who were
pregnant or lactating were excluded from the study. Other
exclusion criteria included patients with active infection, unstable
angina or a history of myocardial infarction within 6 months,
interstitial pneumonia or active lung fibrosis, uncontrolled
diabetes or hypertension, systemic use of corticosteroid or active
concomitant malignancy. Patients with tumour invading the first
rib or more superior chest wall (Pancoast type) were also excluded.
All mediastinal nodes measuring 1.0cm or more in size on
computed tomographic (CT) scans were required to be biopsied to
be histologically benign before patient entry.
Patient eligibility was confirmed by the Japan Clinical Oncology
Group Data Centre before registration. The study protocol was
approved by the institutional review boards at each participating
centre, and all patients provided written informed consent.
Treatment plan
This was an open-label, randomised trial. Patients were randomly
assigned to one of two treatment arms. Dosages of the chemotherapy
were based on the regulatory notes and clinical data in Japan
(Kubota et al, 2004). In the DP combination arm, patients received
D at 60mgm
 2 as a 1-h intravenous infusion followed by P at
80mgm
 2 as a 2-h infusion on day 1. Two cycles of the
chemotherapy were repeated at an interval of 4 weeks. The interval
was permitted to be shortened to 3 weeks, if the patient was judged to
have adequately recovered enough from the first cycle. Surgery
(lobectomy or pneumonectomy with systematic lymph node dissec-
tion) was performed 4–5 weeks after completion or early termination
of the chemotherapy. Patients in the D monotherapy arm received D
at 70mgm
 2 as a 1-h intravenous infusion on day 1. Three cycles of
the chemotherapy were repeated at 3 weeks intervals. Surgery in the D
arm was performed 3–4 weeks after completion or early termination
of chemotherapy. The preoperative periods were thus set at 8–10
weeks in each arm, which was designed to be easier to accept for the
patients and the surgeons.
In each arm, when chemotherapy was judged to be ineffective
with X10% unidirectional tumour growth, or when the patient
experienced unacceptable toxicity (such as, grade 3 neurotoxicity,
grade 2 pulmonary toxicity, grade 3 cardiac toxicity or other grade
4 non-haematological toxicities), chemotherapy was discontinued
and the patient was taken up for surgery as clinically indicated.
With minor toxicities, such as uncomplicated grade 4 haemato-
logic or grade 3 non-critical, non-haematological toxicities,
dosages of subsequent chemotherapy courses were reduced (P by
20mgm
 2 and D by 10mgm
 2).
No protocol therapy was predetermined for those with
unresectable tumours, either during chemotherapy or at operation,
and those with microscopically or macroscopically incompletely
resected tumours. Those who underwent curative resection were
observed until recurrence without additional therapy.
Chemotherapy was supported with routine premedication for
hypersensitivity and antiemetics. For the DP arm, ample hydra-
tion was ensured. Recombinant human granulocyte colony-
stimulating factor was administered when grade 4 neutropaenia
or neutropaenic fever occurred.
Patient evaluation and follow-up
Before study enrolment, a complete medical history and physical
examination, blood cell count determinations, biochemistry testing,
chest X-ray, ECG, CT scan of the chest and CT scan or ultrasound of
upper abdomen were conducted for each patient. Whole-brain CT or
magnetic resonance imaging (MRI) or isotope bone scanning was
performed if clinically indicated. Positron emission tomography
(PET) was not widely available in Japan at the time of the protocol
activation and was not routinely used for staging. Blood cell counts,
differential WBC counts and biochemistry testing were performed
weekly during each course of chemotherapy.
Toxicity of the chemotherapy was evaluated with the National
Cancer Institute Common Toxicity Criteria Tumour (NCI-CTC;
version 2.0). Tumour responses were assessed radiographically
according to the RECIST guideline (Therasse et al, 2000). Response
confirmation at 4 weeks or longer intervals was not necessitated.
Response was assessed by the attending physicians in each
participating institution, and no central confirmation was per-
formed. Chest X-ray was taken at each course, and when suggested
for even minor tumour growth (X10%), confirmatory chest CT
was performed to decide on the continuation of chemotherapy.
After curative resection, the patients were followed up with
periodic reevaluation. This included chest CT every 6 months for
the first 2 years and annually thereafter, until 5 years or tumour
recurrence.
Statistical considerations
This trial was designed as a randomised phase II selection design.
Therefore, formal statistical hypothesis testing of the differences
between the arms, including the calculation of P-values, was not to
be performed. The aim was to select the ‘preferable’ preoperative
chemotherapy arm for a future definitive phase III trial, with the
DFS rate at 1 year as primary end point. The DFS was calculated
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sfrom the date of enrolment by the Kaplan–Meier method, as was
the overall survival (OS).The ‘events’ for the determination of the
DFS included tumour relapse after curative surgery, death from
any cause and non-curative operation. Those with non-curative
operation include patients without surgery and those with
incomplete resection, either microscopically or macroscopically.
Non-curative operation was to be counted as an event on the date
of registration, not on that of surgery. The sample size was
determined to provide sufficient probability to choose the
‘preferable’ arm (Simon et al, 1985). Assuming DFS rates at 1
year of 70 and 80%, 40 patients per arm were required to correctly
select the arm that is not inferior with the probability of 84.9%.
The ‘minimal’ DFS rate of 70% was assumed with the prior report
from North America, in which the 1- and 2-year survival rates were
reported to be 85 and 56%, respectively (Pisters et al, 2000). The
assumption was rough and might well be inaccurate, for no DFS
data were available from the literature. The randomisation was
carried out by the JCOG data centre using a minimisation method
with c-stage (IB vs II) and institutions as balancing factors.
The secondary end points included the objective tumour
response to chemotherapy, complete resection rate, intra- and
post-surgical morbidity/mortality and the OS rate. Tumour
responses in both arms were compared using Fisher’s exact test.
During the accrual period, an interim analysis was planned after
40 patients were randomised and followed up for at least 4 months.
All analyses were performed with the SAS software version 9.1
(SAS Institute, Cary, NC, USA).
RESULTS
Patient characteristics
From October 2002 to October 2003, 80 patients from 18
institutions were enroled and randomised. After 40 patients were
randomised, an interim analysis was carried out. Following the
JCOG Data and Safety Monitoring Committee’s review, the study
was continued. One patient in the D arm was found to be ineligible
because of the wrong histology (sarcoma). All 80 patients were
analysed for characteristics and chemotherapy toxicity, and the 79
eligible patients were analysed for the clinical and pathological
response to chemotherapy, surgical results, DFS and OS.
Table 1 lists the characteristics of the patients, which were well
balanced between the arms.
Chemotherapy delivery and toxicity
Table 2 summarises the chemotherapy delivery, and
Table 3 summarises toxicity in the subject group. Only 60% in
the D arm completed the planned chemotherapy courses, mainly
arising from the clinical ineffectiveness of the therapy. On the
other hand, compliance was very good in the DP arm, and the
toxicity was not greater. Hyponatraemia, probably due to
hydration with P administration, was an unexpected toxicity in
the DP arm, but it was clinically silent and transient in all the cases.
All patients recovered without any particular management, with no
clinically relevant sequelae. Other toxicities were mainly haema-
tologic, and both chemotherapy arms were generally well tolerated
by the patients.
Clinical response and pathological results
Table 4 shows the clinical responses to the chemotherapy. The
overall response rates, 45% in the DP arm and 15% in the D arm,
were compatible with earlier reports for each of the chemotherapy
regimen in patients with NSCLC.
Thoracotomy was performed in 39 of the 40 patients in the DP
arm, and in 37 of the 39 patients in the D arm. The tumour was
surgically resected in 39 (98%) patients in the DP arm, including
pneumonectomy in 3 cases, bi-lobectomy in 2 cases and lobectomy
in 34 cases. Tumour resection was performed in 35 (90%) patients
of the D arm, including pneumonectomy in 1 case, bi-lobectomy in
4 cases and lobectomy in 30 cases. Five patients, including four in
the DP arm and one in the D arm, suffered from massive (X1l)
intraoperative bleeding: due to severe adhesion in three cases (two
in DP and one in D arm), to incomplete suture of the autostapler
resulting in injury of pulmonary artery in one case (DP arm) and
accidental injury to the aorta in one case (DP arm). None was
judged to be related to preoperative therapy. The postoperative
complications included one patient with empyema and another
with pulmonary oedema, both in the DP arm. There were two
surgical deaths, both in the DP arm; one died on postoperative day
59 because of empyema, and another on postoperative day 2
because of massive intraoperative bleeding resulting from surgical
injury to the aorta.
Pathological complete resection (R0), without residual tumour
found either macroscopically or microscopically, was achieved
in 38 (95%) cases in the DP arm, and 34 (87%) cases in the D arm.
Table 2 Delivery of chemotherapy
Arm Cisplatin–docetaxel Docetaxel alone
N 40 40
Completed 38 (95%) 24 (60%)
Not completed 21 6
Ineffective
a 11 1
Adverse event 1 3
Patient refusal 0 1
Found ineligible 0 1
aIneffectiveness was judged upon X10% unidirectional increase in tumour size, and
did not necessarily mean progressive disease by RECIST.
Table 1 Patient characteristics
Arm Cisplatin–docetaxel Docetaxel alone
N 40 40
Clinical stage
IB 22 23
II 18 17
Clinical T stage
T1 5 5
T2 31 29
T3 4 6
Clinical N stage
N0 26 28
N1 14 12
ECOG performance status
PS0 35 31
PS1 5 9
Histology
Adenocarcinoma 30 24
Squamous cell carcinoma 10 11
Others 0 5
Body weight loss within 6 months
None 24 22
p5kg 13 14
45kg 1 2
Missing 2 2
Smoking
Median smoking 40 pack-years 40 pack-years
Never-smoker 6 8
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sOn pathological examination, 23% of the 75 patients who
underwent surgery were found to have N2 or N3 status. Pathologic
CR was achieved in two patients, both in the DP arm. Clinical
N-stage was poorly correlated to pathological nodal status
(Table 5).
DFS and OS
The DFS and OS were updated in November 2007. The DFS
rates at 1, 2 and 4 years were 78, 65 and 57% in the DP arm, and
were 62, 44 and 36% in the D arm, respectively (Figure 1).
Table 6 summarises the outcome at 1 year, the primary end point
of the study. The DFS rate at 1 year was 78% (31 out of 40) in the
DP arm, which was consistent with the study assumption that it
would be 80% in the ‘better’ arm, whereas it was a disappointing
62% (24 out of 39) in the D arm. The 16% difference was more than
presumed in the protocol.
The OS rates at 1, 2 and 4 years were 88, 83 and 75% in the DP
arm, and were 87, 72 and 57% in the D arm, respectively (Figure 2).
Both the DFS and the OS rates were better in the DP arm. The
OS was better in the DP arm in both adenocarcinoma and
non-adenocarcinoma histological subtypes.
DISCUSSION
As compared with post-surgical adjuvant therapy, preoperative
chemotherapy has several practical as well as theoretical advan-
Table 3 Toxicity of chemotherapy
Arm Cisplatin–docetaxel Docetaxel alone
N 40 40
Grade 2/3/4 (% grade 3+4) 2/3/4 (% grade 3+4)
Haematological
Leukopaenia 18/14/1 (38) 12/15/2 (43)
Neutropaenia 5/16/17 (83) 5/10/21 (78)
Anaemia 4/0/0 (0) 7/0/0 (0)
Thrombocytopenia 1/0/0 (0) 0/0/0 (0)
Nonhaematological
Total bilirubin 4/0/0 (0) 0/0/0 (0)
Serum AST 0/0/0 (0) 3/1/0 (3)
Serum ALT 5/0/0 (0 5/1/0 (3)
Serum creatinine 3/0/0 (0) 0/0/0 (0)
Hypoxia 0/0/0 (0) 3/0/0 (0)
Hypercalcaemia 0/0/0 (0) 0/1/0 (3)
Hyponatraemia  /6/0 (15)  /1/0 (3)
Hypersensitivity 0/0/0 (0) 0/1/0 (3)
Fatigue 3/1/0 (3) 0/0/0 (0)
Constipation 4/1/0 (3) 5/0/0 (0)
Diarrhea 3/3/0 (8) 2/0/0 (0)
Nausea 9/7/  (18) 0/0/  (0)
Vomiting 5/1/0 (3) 0/0/0 (0)
Febrile neutropaenia  /1/0 (3)  /0/0 (0)
Infection with neutropaenia  /2/0 (5)  /3/0 (8)
Infection without neutropaenia 1/0/0 (0) 4/2/0 (5)
Neuropathy 0/0/0 (0) 1/0/0 (0)
Any grade 3/4 toxicity 35 (88%) 32 (80%)
Any grade 3/4
Non-haematological toxicity 15 (38%) 9 (23%)
Table 4 Clinical response to chemotherapy based on RECIST
Arm Cisplatin–docetaxel Docetaxel alone
N 40 39
Completed chemotherapy 38 (95%) 24 (62%)
CR 1 0
PR 17 6
CR+PR 18 6
SD 18 23
PD 4 10
NE 0 0
ORR 45% 15%
(95% confidence interval) (29–62%) (6–31%)
CR¼complete response; NE¼not evaluable; ORR¼overall response rate;
PD¼progressive disease; PR¼partial response; RECIST¼Response Evaluation
Criteria in Solid Tumor; SD¼stable disease.
Table 5 Pathological results
Arm
Cisplatin–docetaxel Docetaxel alone
c-N stage N0 N1 Total N0 N1 Total
Number of cases 26 14 40 27 12 39
p-N0 17 6 23 18 4 22
p-N1 3 5 8 3 1 4
p-N2 5 2 7 5 4 9
p-N3 1 0 1 0 0 0
Not assessable 0 1 1 1 3 4
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0123
D
DP
Years after registration
456
DP arm (n=40)
DP arm (n=39)
P
r
o
p
o
r
t
i
o
n
 
d
i
s
e
a
s
e
 
f
r
e
e
Figure 1 Disease-free survival.
Table 6 Outcome at 1 year
Arm Cisplatin–docetaxel Docetaxel alone Total
Number of cases 40 39 79
Alive, disease-free 31 24 55
Alive with disease 4 11 15
Dead, due to cancer 3 2 5
Dead, treatment-related 2 0 2
Dead, other causes 0 2 2
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Figure 2 Overall survival.
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stages (Pisters et al, 2000; Pisters, 2003). The practical advantages
include better patient tolerance and clinical visualisation of
chemotherapy effect.
There are very few reports as to the optimal preoperative
therapy strategy. The majority of trials have used ‘standard’
platinum-based doublets (Pisters, 2003). Although they are the
‘standard’ for advanced, stage IV NSCLC, a trade-off between the
cytotoxic effect and toxicity of the chemotherapy, not only toxicity
itself but also its influence on surgery and post-surgical morbidity
and mortality (Depierre et al, 2002; Pisters et al, 2007), must be
considered for preoperative therapy.
In this randomised phase II study, we evaluated DP combination
chemotherapy and D monotherapy as preoperative treatment for
early stage NSCLC. Although the DFS assumptions of the protocol,
70 vs 80% at 1 year, were rough and arbitrary due to lack of
historical data, subsequent S9900 trial (Pisters et al, 2007) showed
DFS rate of 68% in the surgery alone group and 69% in those with
preoperative carboplatin–paclitaxel therapy, consistent with our
assumption.
Our results showed that single-agent D was inadequate in this
setting; an unexpectedly high progression rate led to an early
chemotherapy termination rate of as high as 40%. The reason for
the high PD rate is unknown. In addition, we tried to minimise the
disadvantage of continuation of ineffective chemotherapy by
defining the ineffectiveness as X10% tumour size increase instead
of X20% in the RECIST guideline (Therasse et al, 2000). This
subtle decision rule might require centralised confirmation. The
DFS rate in the D arm was disappointing and was, in fact, very
similar to that in the surgery-alone arm in the S9900 study in the
United States (Pisters et al, 2007).
On the other hand, both the DFS and OS rates of the DP arm
were promising. Disease-free survival at 1 year of 78% was fully
consistent with the estimation in the study protocol. Although our
data do not refute other platinum-based chemotherapy as
candidates of preoperative treatment, it would be justified to
conclude that DP was active and promising, regardless of
disappointing data of D monotherapy. One might argue that DFS
at 1 year was too premature as an end point. Because the DFS and
OS curves of the DP arm seem to have reached to plateau at
2 years, DFS at 2 years might be a more appropriate end point.
The number of chemotherapy courses of the DP combination
was two, whereas many previous studies used three courses. In
the North American trials with carboplatin and paclitaxel,
three preoperative courses appeared to have no advantage when
compared with two courses (Pisters et al, 2000; Pisters, 2003).
Although patients with ‘two preoperative courses’ were to have two
additional courses after the operation, compliance to the post-
surgical courses was very poor anyway (Pisters et al, 2000). But, as
the majority of the patients appeared fit enough after two courses
of DP and a major operation, we could consider the addition
of a couple of postoperative chemotherapy cycles at least for
responders.
One of the major disadvantages of preoperative therapy is the
inaccuracy of the clinical staging, as reported by Depierre et al
(2002). In our trial, 23% of the 74 patients who underwent
thoracotomy were found to have p-N2/N3 disease. In Japan,
mediastinoscopy for patients with mediastinal nodes measuring
1cm or less in size on CT is not performed as a routine clinical
practise, and nor was it in our study. Although the introduction of
PET may improve the accuracy of the clinical staging, it would still
be unlikely to be comparable to surgical staging (Lardinois et al,
2003; Cerfolio et al, 2004; Shim et al, 2005). This would inevitably
lead to heterogeneity of the patient population, necessitating a
sophisticated study design and large sample size for any future
trial on preoperative therapy.
We conclude that the DP combination regimen is active and well
tolerated as preoperative chemotherapy, with highly promising
survival data. Future clinical trials are warranted based on our
results.
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